読み込み中
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
前日終値
$4.97
−$0.15 · -2.93%
日中の時刻はETです。市場データは遅延する場合があります。
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
日中レンジ
現在 $4.97
52週レンジ
現在 $4.97
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
43
適正価値
センチメント
54
まちまち
リスク
75
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
日中レンジ
現在 $4.97
52週レンジ
現在 $4.97
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 5266 USD | 4268 USD | 240 USD | — | — |
| 粗利益 | −5266 USD | −4268 USD | −240 USD | — | — |
| 研究開発 | 146.67万 USD | 34.22万 USD | 95.46万 USD | 160.89万 USD | 13.72万 USD |
| 販売・一般管理 | 476.56万 USD | 331.66万 USD | 179.7万 USD | 162.6万 USD | 171.87万 USD |
| 営業費用 | 623.75万 USD | 365.88万 USD | 275.16万 USD | 129.4万 USD | 33.43万 USD |
| 受取利息 | 26.34万 USD | 9.58万 USD | 2134 USD | 1554 USD | 2424 USD |
| 支払利息 | 9522 USD | 9270 USD | 5.29万 USD | — | — |
| 減価償却費と償却費 | 5266 USD | 4268 USD | 240 USD | — | 234.83万 USD |
| 営業利益 | −623.75万 USD | −366.3万 USD | −275.18万 USD | −437.53万 USD | −33.43万 USD |
| 純利益 | −693.64万 USD | 101.18万 USD | −5115.9万 USD | 801.43万 USD | 823.04万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
